A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea

BACKGROUND: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy. METHODS: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in S...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hee Seung, Chung, Moon Jae, Park, Jeong Youp, Bang, Seungmin, Park, Seung Woo, Kim, Ho Gak, Noh, Myung Hwan, Lee, Sang Hyub, Kim, Yong-Tae, Kim, Hyo Jung, Kim, Chang Duck, Lee, Dong Ki, Cho, Kwang Bum, Cho, Chang Min, Moon, Jong Ho, Kim, Dong Uk, Kang, Dae Hwan, Cheon, Young Koog, Choi, Ho Soon, Kim, Tae Hyeon, Kim, Jae Kwang, Moon, Jieun, Shin, Hye Jung, Song, Si Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228666/
https://www.ncbi.nlm.nih.gov/pubmed/28072706
http://dx.doi.org/10.1097/MD.0000000000005702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228666/
https://www.ncbi.nlm.nih.gov/pubmed/28072706
http://dx.doi.org/10.1097/MD.0000000000005702

Ejemplares similares